瑞典31 670例薄层黑色素瘤患者的生存分析
基于瑞典黑色素瘤登记处1990–2017年确诊的31 670例薄层皮肤恶性黑色素瘤(CMM,≤1 mm)患者,计算黑色素瘤特异性生存(MSS)和条件MSS(CMSS)。总体10年和20年MSS分别为97%(95%CI 97–97)和95%(95%CI 95–96);厚度≥0·7 mm后MSS随厚度增加显著下降,但各厚度组生存随时间改善,女性MSS和CMSS均优于男性。
要点
- 薄层CMM总体10年MSS为97%,20年为95%。
- 厚度≥0·7 mm后MSS随厚度增加显著下降。
- 各厚度组生存随时间改善,女性MSS和CMSS优于男性。
核心结论
- 瑞典薄层CMM患者MSS极佳,厚度≥0·7 mm者MSS下降但长期生存和CMSS良好,不支持比现行推荐更扩展的随访方案。
研究设计与样本
- 基于瑞典黑色素瘤登记处的 population-based 研究,纳入1990–2017年确诊的31 670例薄层CMM(≤1 mm)患者,随访至2017年底。
- 采用Kaplan-Meier法计算不同厚度组的MSS和CMSS,Cox回归分析比较组间生存差异。
主要发现
- 总体10年MSS为97%(95%CI 97–97),20年MSS为95%(95%CI 95–96)。
- 从0·7 mm及以上,MSS随厚度水平增加而显著下降。
- 所有厚度组生存随时间改善;男性1·0 mm组CMSS最低,但其10年CMSS随时间稳步增加。
- 女性总体MSS和CMSS均优于男性,但MSS与CMSS的关系在两性间相似。
临床怎么用
- 薄层CMM患者长期生存极佳,临床随访可参照瑞典现行推荐,无需因厚度≥0·7 mm而扩展随访方案。
- 男性及厚度≥0·7 mm患者MSS相对较低,应关注但CMSS仍非常有利。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cutaneous malignant melanoma (CMM) continues to increase in most countries worldwide and the majority are diagnosed with thin tumours (≤ 1 mm). OBJECTIVES: The aim of the present study was to investigate the melanoma-specific survival (MSS) as well as conditional MSS (CMSS) in patients with thin CMM in Sweden. PATIENTS AND METHODS: Clinical and histological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with thin CMM between 1990 and 2017. Patients were followed until the end of 2017. MSS as well as CMSS for different thickness groups were calculated using the Kaplan-Meier method and Cox regression analyses were used to calculate for survival differences between thickness groups. RESULTS: There were 31 670 patients included for final analyses. The overall 10- and 20-year MSS for thin CMMs was 97% [95% confidence interval (CI) 97-97] and 95% (95% CI 95-96), respectively. From 0·7 mm and above, MSS decreased significantly with increasing thickness level. All thickness groups had an increased survival over time. The lowest CMSS was confirmed for men with 1·0 mm in thickness but their 10-year CMSS increased steadily over time. Women had overall better MSS as well as CMSS than men. However, the relation between MSS and CMSS was similar for both sexes. CONCLUSIONS: MSS was confirmed as excellent for patients with thin CMMs in Sweden. Although we could show a decreased MSS for patients with 0·7 mm thickness and above, the long-term survival and, in addition, a very favourable CMSS for those patients do not support more extended follow-up programmes than the current recommendations in Sweden.
引用
- Isaksson K, Mikiver R, Eriksson H, et al. Survival in 31 670 patients with thin melanomas: a Swedish population-based study. Br J Dermatol. 2020. PMID: 32133615. doi:10.1111/bjd.19015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。